In particular, we focused on the effect of AZD5363 (an AKT inhibitor), AZD2014 (an mTOR inhibitor), and BEZ235 (a dual PI3K/mTOR inhibitor) alone or in combination on two bladder cancer cell lines differing in their mTOR mutation status. This evidence concerns the gene AKT1 and urinary bladder cancer.